RecruitingPhase 3NCT07165951
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Studying Catastrophic antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Intervention
- TQB2868 Injection(drug)
- Enrollment
- 566 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
- Anhui Provincial Cancer Hospital, Hefei, Anhui, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing Municipality, China
- The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, Beijing Municipality, China
- Beijing Daxing District People'S Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Mengchao Hepatobiliary Hospital OF Fujian Medical University, Fuzhou, Fujian, China
- The Firstaffiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
- Gansu Provincial Hospital, Lanzhou, Gansu, China
- The First Hospital of Lanzhou University, Lanzhou, Gansu, China
- Lanzhou University Second Hospital, Lanzhou, Gansu, China
- Sun Yat-Sen University, Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07165951 on ClinicalTrials.govOther trials for Catastrophic antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07458984FMT Capsules for rCDIHelsinki University Central Hospital
- RECRUITINGPHASE1NCT07297199A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55Biogen
- RECRUITINGNANCT07561333Comparing ACB+IPACK and ACB+BiFeS Block Combinations for Analgesia in Total Knee ArthroplastyHitit University
- RECRUITINGPHASE2, PHASE3NCT06841679Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaBeijing Biostar Pharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07044271A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsEli Lilly and Company
- RECRUITINGPHASE1NCT06943677A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant TumorsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT06822946Zhibitai Capsules for the Treatment of Primary HyperlipidemiaChengdu Diao Jiuhong Pharmaceutical Factory
- RECRUITINGPHASE1NCT06796699A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid TumorsSuzhou Genhouse Bio Co., Ltd.